INVO Bioscience (INVO) Tops Q3 EPS by $1.50
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts INVO Hot Sheet
Join SI Premium – FREE
INVO Bioscience (NASDAQ: INVO) reported Q3 EPS of ($0.70), $1.50 better than the analyst estimate of ($2.20). Revenue for the quarter came in at $970 thousand versus the consensus estimate of $1.82 million.
For earnings history and earnings-related data on INVO Bioscience (INVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Moody’s lifts Nokia to Baa3 investment grade on AI and cloud momentum
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
